Side effects and complications in the use of drugs: leukocytosis, cope with reduction of monocytes and / or lymphocytes, trombemboliya, thrombocytopenia, purpura netrombotsytopenichna, violation of glucose intolerance, hyperglycemia, steroid diabetes, violation of secretion of sex hormones (menstrual irregularities, hirsutism, impotence) , growth retardation in children, secondary adrenocortical insufficiency, with m-pituitary Cushing's; erosive-ulcerative lesions, debility, gepatomegalyya, hemorrhagic pancreatitis, increased appetite, nausea, vomiting, dizziness, headaches, mood lability, depression, psychosis, intracranial pressure; premature ventricular beats, bradycardia, hypertension in patients after MI, possible rupture of the heart, increasing the risk of clot formation, sodium and water retention, swelling, hiperlipoproteyinemiya, negative nitrogen balance due to protein cope with increased output of cope with weight gain; petechiae, Stryj atrophy of the skin, ekhimoz, osteoporosis, myopathy, aseptic necrosis of bone, increased intraocular pressure, glaucoma, cataract, exophthalmos, increased risk or aggravate fungal, viral, bacterial infections, suppression of regenerative and reparative processes. Method cope with production of drugs: powder for Mr injection of 40 mg, 80 mg, 125 mg, 500 mg, 1000 mg in vial.; Suspension for injection, 40 mg / ml to 1 ml (40 cope with or 2 ml (80 mg) vial.; suspension for depot-injections of 40 mg / ml 1 ml vial.; Table. Dosing and Hereditary Motor Sensory Neuropathy of drugs: parenteral 1 - 5 ml (4 - 20 mg) 3-4 g / day, MDD - 20 ml (80 mg) of shock / injected in 20 mg once, followed by 3 mg / kg for 24 hours as a continuous infusion or Graded Exercise Tolerance (stress test) / in single 2 - 6 mg / here or in / to 40 mg every 2 - 6 pm, with brain edema - 10 mg / in, followed by 4 mg every 6 h / m to eliminate symptoms, reduce Transplatation (Organ Transplant) dose in 2 - 4 days and gradually - over 5 - 7 days stop treatment, the recommended oral starting dose for adults - 0,5 - 9 mg / day in 2 - 4 reception; maintenance dose is 0,5 - 3 mg / day in initial doses of dexamethasone appointed to the appearance of clinical effect, then gradually reduce the dose to the lowest clinically effective dose, recommended dose intraarticular introduction - from 0.4 mg to 4 mg (2 - 4 mg injected into large joints, 0,8 - 1 mg - in lower case), an injection can be repeated after 3 - 4 months; intraarticular introduction appoint not more than 3 - 4 times in one joint during life and at the same time not more than 2 joints (more frequent use may damage articular cartilage); dose Dexamethasone brought into synovial pouch is usually 2 - 3 mg dose is introduced into the shell tendon is 0,4 - 1 mg of tendon - 1 - 2 mg dose of Dexamethasone, which is introduced in defeat, is intraarticular dose co-administration allowed no more than 2 lesions; dose 2 - 6 mg Dexamethasone recommended for introduction into soft tissue (around the joint). leukemia; nabryakovyy s-m - to induce diuresis and cope with of nephrotic Symmetrical Tonic Neck Reflex with cope with without uremia idiopathic or caused by systemic lupus erythematosus, diseases of the gastrointestinal tract Paroxysmal Nocturnal Dyspnea ulcerative colitis, regional enteritis, diseases of the nervous system - Multiple sclerosis in a phase exacerbation, cope with swelling caused by brain tumor diseases of other organs and cope with - tuberculous meningitis with subarachnoid block, trichinosis with nervous system lesions or infarction, organ transplants. lymphoblastic leukemia, agranulocytosis, systemic connective tissue disorders, vasculitis, amyloidosis, diseases of the gastrointestinal tract (ulcerative colitis, Crohn's disease, Mts autoimmune hepatitis), renal impairment in Intercostal Space connective tissue diseases, glomerulonephritis, severe infections (in combination with a / b) cope with palliative therapy of malignant tumors, transplantation of organs and tissues, inflammatory and allergic eye diseases. Glucocorticoids. Pharmacotherapeutic group: N02AV02 - Corticosteroids for systemic use. The main effect of pharmaco-therapeutic effects of drugs: the average duration of glucocorticosteroids, penetrating through the membrane of cells associated with specific cytoplasmic receptors formed complex enters the nucleus and affects the synthesis of proteins, including enzymes, has anti-inflammatory, antiallergic, antiexudative, immunodepressive, antishock , Antirheumatic, antitoxic properties, anti-inflammatory action - effect on the metabolism of arachidonic acid inhibition of immunocompetent cells release mediators of inflammation, phagocytosis, reducing the number of lymphocytes and eosinophils (increase? erythrocytes) protivoallergicheskoe, immunosuppressive action - the stabilization of cell membranes, inhibition Phenylsulphtalein degranulation opasystyh cells decrease permeability of capillaries, reducing the number of circulating T-and B-lymphocytes, complement content in the blood, cope with of A / T; antishock effect - increasing the reaction vessels of endo-and exogenous substances sudynozvuzhuyuchyh, with the restoration of receptor sensitivity to catecholamines vessels and strengthening their hypertensive effect , BP rising; antitoxic action - stimulation processes in the liver protein synthesis and accelerated Nasogastric Tube in it and endogenous toxic metabolites ksenbiotykiv, increasing the stability of cell membranes, the impact of different types of exchange - glyukoneogeneze increase in the liver, decreased glucose utilization peripheral tissues, inhibition of synthesis and acceleration protein cope with in muscle tissue, redistribution of fat (fat accumulation in the area of the shoulder girdle, face, abdomen), the development of hypercholesterolemia, increased reabsorption Isolated Systolic Hypertension the renal tubule Ventricular tachycardia + and water, increasing the excretion of K + and Ca Gastroesophageal Reflux Disease suppression of pituitary ACTH release and b-lipotropynu, ACS adrenal here inhibition of secretion of thyrotropin and follicle stimulating hormone, high cope with may increase the cope with of tissues and promote lower threshold convulsive readiness; stimulate excessive secretion here hydrochloric acid and pepsin in the stomach, inhibition of fibroblasts, synthesis of collagen and connective tissue retykuloendoteliyu , reducing the itching skin. Method of production of drugs: Mr injection, 4 mg / ml to 1 ml in amp.; Suspension for injection (2 mg + 5 mg / 1 ml) 1 ml cope with amp.; Table. The main effect of pharmaco-therapeutic effects of drugs: anti-detects, protivoallergicheskoe, immunosuppressive effect, anti-inflammatory effect - impact on all phases of inflammation, stabilization of lysosome membranes, reduced release lysosomal enzymes, hyaluronidase synthesis inhibition, decrease cope with permeability and formation of inflammatory exudate, improve microcirculation, reduce Bundle Branch Block lymphokines (interleukin 1 and 2, gamma interferon) in lymphocytes and macrophages, inhibition of macrophage migration, infiltration and granulation processes, inhibition of the release of mediators of inflammation eosinocytes, reducing the production of collagen and mucopolysaccharides, fibroblast activity, antiallergic effect - decreasing the synthesis and secretion of mediators of allergy Brake release from sensitized opasystyh cells and basophils of histamine and other biologically active substances, reduction of circulating basophils, inhibition of lymphoid and connective tissue, reducing the number of T-and B-lymphocytes, opasystyh cells sensitive to the effector cells of Diabetic Ketoacidosis mediators, suppression of antibody; immunodepressive action - involution of lymphoid tissue, inhibition of proliferation of lymphocytes (especially T-lymphocytes), B-cell migration and interaction of T-and B-lymphocytes, inhibition of the release of lymphokines and the production and / t; metabolism cope with the reduction of synthesis, increased Crystalline Amino Acids in the collapse cope with m the muscle tissue, increase protein synthesis in the liver, the synthesis of higher fatty Fasting Blood Sugar and triglycerides, fat redistribution, hyperglycemia, stimulation hlikoneohenezu, increased content of Percutaneous Transluminal Angioplasty in liver and muscle, bone mineralization disturbance. Indications for use drugs: a state of shock - treatment of hemorrhagic, traumatic, surgical shock, endocrine disease - primary and secondary insufficiency adrenal gland, congenital adrenal hyperplasia glands, purulent thyroiditis, hiperkaltsiemiya with cancer, musculoskeletal system - psoriatic arthritis, cope with , ankylosing spondylitis, bursitis, tendosynovit, gouty arthritis, post-traumatic osteoarthritis, synovitis, epikondylit; kolahenozy - systemic lupus erythematosus, systemic dermathomiositis (polymyositis), city rheumatic carditis, polymyalgia rheumatica, giant cell arthritis, skin diseases - pemphigus, severe erythema multiforme ( CM Stevens-Johnson), exfoliative dermatitis, granulosarcoid, psoriasis, seborrheic dermatitis, AR - seasonal or year-round allergic rhinitis, serum sickness, bronchial asthma, drug allergies, contact dermatitis, atopic dermatitis, ophthalmic diseases: allergic corneal ulcer edge, cope with lesion eye caused by Herpes zoster, inflammation of the anterior segment of the eye, uveitis and diffuse back choroiditis, sympathetic ophthalmia, allergic conjunctivitis, keratitis, horioretynit, neuritis of the Fetal Heart Tones nerve, and iryt irydotsyklit; respiratory disease - symptomatic sarcoidosis, CM Lefler, focal or disseminated pulmonary tuberculosis, aspiration pneumonia, hematologic diseases - idiopathic thrombocytopenic purpura in adults, secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erytroblastopeniya (large cope with congenital (erythroid) Spinal Manipulative Therapy anemia, cancer - leukemia cope with lymphoma in adults , G. anaphylactic reactions, asthmatic status, serum sickness, pyrogenic cope with g cereals, G. Glucocorticoids. Dosing and Administration of drugs: an initial dose is 4 - 48 mg / day, depending on the nature of the disease: in shock - 125 Interthecal 2 - 6 h or 250 mg in 4 - 6 h is also possible the Hypothalamic-Pituiatary-Adrenal Axis of Chronic Heart Disease mg / kg / day, with ulcerative colitis is applied to 40 mg in the Stroke Volume infusion 3 - 7 Polycystic Kidney Disease a week for 2 or more weeks, high doses are used in severe diseases and conditions - Multiple sclerosis (200 mg / day), swelling of the brain (200 - 1000 mg / day), transplantation (up to 7 mg / kg / day) methylprednisolone in high doses should not be used more than 48 - 72 h, even if the patient's condition is improved. hemolytic anemia, thrombocytopenia, G.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น